Abstract
[...]a prespecified subgroup analysis of resectable patients in the largest of these trials, PREOPANC, failed to demonstrate survival benefit. [...]dose reductions were observed in over twothirds of patients in the neoadjuvant arm - not typical of contemporary practice at experienced centers routinely delivering these therapies in the neoadjuvant setting. [...]the bizarre association between higher rates of margin-Znodenegative resection with worse survival in the neoadjuvant arm of this trial is difficult to reconcile with multiple lines of prior evidence.